Anti-pulmonary fibrosis application of small interfering RNA of Fstl 1

Abstract

The invention discloses an application of small interfering RNA of Fstl 1 in anti-pulmonary fibrosis. Pharmacology experiments confirm that the small interfering RNA of Fstl 1 can effectively reduce a mortality rate of bleomycin-instilled mice, and pulmonary damage and pulmonary fibrosis which are induced by bleomycin can be reduced significantly via decreasing expression of Fstl 1, thereby indicating that the small interfering RNA of Fstl 1 can be used for preparing drugs for preventing and / or treating pulmonary fibrosis.

Description

technical field [0001] The invention relates to a new application of small interfering RNA of Fstl1 in preventing and treating pulmonary fibrosis, and belongs to the technical field of medicine. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease characterized by pathological changes of usual interstitial pneumonia (UIP). The course of the disease is generally progressive and the prognosis is poor. , The average survival time after diagnosis is 2-4 years. Its etiology is complicated, its pathogenesis is not yet clear, and there is no effective treatment in clinical practice. Although the research on the pathogenesis of idiopathic pulmonary fibrosis has been carried out in depth from the aspects of cells, cytokines, extracellular matrix (ECM), cell signal transduction pathways, etc., the exact pathogenesis has not yet been clarified, so its treatment is mainly It starts from inhibiting pulmonary fibrosis and ...

AI Technical Summary

Problems solved by technology

The etiology is complex, the pathogenesis is still unclear, and there is no effective treatment in clinical practice.

Although the research on the pathogenesis of idiopathic pulmonary fibrosis has been carried out in depth from the aspects of cells, cytokines, extracellular matrix (ECM), cell signal transduction pathways, etc., the exact pathogenesis has not yet been clarified, so its treatment is mainly It starts from inhibiting pulmonary fibrosis and improving pulmonary fibrosis, so it also lacks specificity and effectiveness in treatment

Images